Quebec Pancreas Cancer Study (QPCS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04104230

Recruitment Status : Recruiting

First Posted : September 26, 2019

Last Update Posted : February 23, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

George Zogopoulos, McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Description

Brief Summary:

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Condition or disease
Pancreas Cancer Pancreatic Cancer Pancreas Neoplasm Pancreas Cyst Pancreatic Precancerous Condition Familial Pancreatic Cancer Hereditary Cancer Bile Duct Cancer Ampullary Cancer Duodenal Cancer Gallbladder Cancer

Detailed Description:

The objectives of the QPCS are as follows:

To study the epidemiology of pancreas cancer, related cancers and related pre-cancerous conditions, including the risk factors and patient outcomes.
To characterize the contribution of known hereditary cancer syndromes to pancreas cancer, related cancers, and related pre-cancerous conditions.
To identify new genetic and epigenetic changes associated with hereditary pancreas cancer, related cancers, and related pre-cancerous conditions. DNA contains the instructions used in the development and functioning of living organisms, including humans. Epigenetic changes are changes other than changes in the underlying DNA sequence.
To study the tumour biology of pancreas cancer and related pre-cancerous conditions. This may include studying the tumour and the environment surrounding the tumour, as well as blood and/or saliva samples. The studies may include characterization of genetic, genomic, transcriptomic, epigenetic, proteomic, and metabolomic changes.
To identify and characterize biomarkers associated with pancreas cancer, related cancers and related pre-cancerous conditions.
To determine if there are any epidemiological, clinical and outcome (for example, overall survival) associations with the genetic, genomic, epigenetic, transcriptomic, proteomic, metabolomic or other biologic changes that occur in pancreas cancer, related cancers and related pre-cancerous conditions.

Study Design

Layout table for study information

Study Type :	Observational [Patient Registry]
Estimated Enrollment :	2000 participants
Observational Model:	Case-Control
Time Perspective:	Prospective
Target Follow-Up Duration:	5 Years
Official Title:	Quebec Pancreas Cancer Study
Actual Study Start Date :	March 12, 2012
Estimated Primary Completion Date :	January 2025
Estimated Study Completion Date :	January 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatic Cancer

Genetic and Rare Diseases Information Center resources: Pancreatic Cancer Bile Duct Cancer Gallbladder Cancer Familial Pancreatic Cancer

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Individuals Affected With Pancreatic Cancer Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
Individuals Affected with Related Cancer Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
Individuals Affected With Pancreatic Neoplasm Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
High-Risk Individuals Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
Healthy Controls Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.

Outcome Measures

Primary Outcome Measures :

Knowledge and Tissue Bank [ Time Frame: 10 years ]
Create a knowledge and tissue bank for pancreatic cancer, related pre-cancerous lesions, and related cancers, including patient demographics, type of chemotherapy treatments, type of surgical procedures, other procedures, overall survival, progression-free survival, epidemiological risk factors, genetic factors and characteristics of tumour tissue.

Biospecimen Retention: Samples With DNA

Blood and/or saliva samples, tumor/tissue samples.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Sampling Method:	Non-Probability Sample

Study Population

Individuals diagnosed with pancreatic cancer or related cancer followed in a hospital in Quebec.

High-risk individuals with Familial Pancreatic Cancer or hereditary predisposition to pancreatic cancer with or without a family history of pancreatic cancer.

Healthy controls.

Criteria

Inclusion Criteria:

Individual diagnosed with pancreatic cancer.
Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer).
Individual diagnosed with pancreatic neoplasm or pancreatic cyst.
High-risk individuals with Familial Pancreatic Cancer (3 or more relatives affected with adenocarcinoma).
High-risk individuals with 2 first-degree relatives affected with young-onset pancreatic adenocarcinoma (≤ 50 years old).
High-risk individuals with one of the following Hereditary Cancer Syndromes: Peutz-Jeghers Syndrome (STK11 gene mutation), Familial Atypical Multiple Mole Melanoma Syndrome (CDKN2A gene mutation), or Hereditary Pancreatitis (PRSS1 gene mutation) with clinical manifestations.
High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITH a family history of cancer.

Exclusion Criteria:

High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITHOUT a family history of cancer.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04104230

Contacts

Layout table for location contacts

Contact: Adeline Cuggia, MSc	514-934-1934 ext 76333	cancer.pancreas@mcgill.ca

Locations

Layout table for location information

Canada, Quebec
McGill University Health Centre	Recruiting
Montréal, Quebec, Canada, H4A 3J1
Contact: Adeline Cuggia, MSc 514-934-1934 ext 76333 cancer.pancreas@mcgill.ca
Principal Investigator: George Zogopoulos, MD, PhD

Sponsors and Collaborators

George Zogopoulos

Investigators

Layout table for investigator information

Study Director:	George Zogopoulos, MD, PhD	McGill University Health Centre/Research Institute of the McGill University Health Centre

More Information

Publications:

Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenery D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol. 2015 Apr;22(2):113-21. doi: 10.3747/co.22.2300.

Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Lett. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.

Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, Bascuñana C, Borgida A, Hall A, Whelan T, Holter S, McPherson T, Cleary S, Petersen GM, Omeroglu A, Saloustros E, McPherson J, Stein LD, Foulkes WD, Majewski J, Gallinger S, Zogopoulos G. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Lett. 2016 Jan 28;370(2):302-12. doi: 10.1016/j.canlet.2015.10.030. Epub 2015 Nov 3.

Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology 2018 :2, 1-16.

Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834.

Layout table for additonal information

Responsible Party:	George Zogopoulos, Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre
ClinicalTrials.gov Identifier:	NCT04104230
Other Study ID Numbers:	2018-3171
First Posted:	September 26, 2019 Key Record Dates
Last Update Posted:	February 23, 2021
Last Verified:	February 2021

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by George Zogopoulos, McGill University Health Centre/Research Institute of the McGill University Health Centre:


Cancer Genetics

Additional relevant MeSH terms:

Layout table for MeSH terms

Pancreatic Neoplasms Gallbladder Neoplasms Bile Duct Neoplasms Precancerous Conditions Duodenal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases	Endocrine System Diseases Biliary Tract Neoplasms Biliary Tract Diseases Gallbladder Diseases Bile Duct Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Gastrointestinal Diseases Duodenal Diseases Intestinal Diseases

To Top